profit from every $100 of sales.
$0$100
Coherus Oncology
$0.53-2.41% today
-58.3% in 1 year
1-year low $0.531-year high $2.51
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $0.48 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Coherus Oncology sold, what it kept, and what it did with the cash.
Sales went from $211 million in 2022 to $42.2 million in 2025, with $168 million of profit last year.
SalesProfit
Coherus Oncology vs. similar companies
Coherus Oncology grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Coherus Oncology | 0.5× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Coherus Oncology's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 211 | 257 | 26 | 42 | |
| 141 | 98 | 18 | 28 | |
| -257 | -203 | -200 | -181 | |
| -256 | -194 | -199 | -170 | |
| -292 | -238 | 29 | 168 | |
| -3.76 | -2.53 | 0.25 | 1.43 | |
| 66.8% | 38.2% | 66.9% | 67.2% | |
| -121.7% | -79.0% | -756.6% | -429.5% | |
| -138.2% | -92.5% | 108.0% | 398.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 481 | 630 | 449 | 258 |
| Cash | 64 | 103 | 126 | 89 |
| Total debt | 480 | 481 | 270 | 40 |
| Total liabilities | 618 | 823 | 581 | 197 |
| -137 | -193 | -132 | 61 | |
| 78 | 94 | 115 | 117 | |
| -59.7% | -54.3% | -117.2% | -135.7% | |
| 212.3% | 123.0% | -21.6% | 275.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -241 | -175 | -20 | -139 | |
| 2 | 0 | – | – | |
| -241 | -175 | -20 | -139 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 51 | 43 | 28 | 17 |
Valuation
- 0.5×
- –
- –
- 3.0×
- 1.9×
- –
- –
- -170.6%
- 206.9%
- 0.0%
Profitability
- 67.2%
- -429.5%
- 398.4%
- -354.1%
- -142.9%
- -74.1%
- -174.7%
- -57.0%
- -127.0%
- 218.2%
Growth
- −41.5%
- –
- −577.7%
- –
- +12.4%
Financial health
- -0.3×
- 0.01
- 0.4%
- -18.8×
- 1.54
- 1.43
- 0.18
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 563
Bottom 2%of 868
What analysts expect
- Average price target
- $6.02
- Range
- $1.05 – $11.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.25 | -0.26 | +5.1% |
| Mar 9, 2026 | -0.34 | -0.36 | +4.2% |
| Nov 6, 2025 | -0.33 | -0.32 | −3.1% |
| Aug 7, 2025 | -0.34 | -0.31 | −9.7% |
| May 12, 2025 | -0.35 | -0.31 | −12.9% |
| Mar 10, 2025 | -0.28 | -0.10 | −180.0% |
| Nov 6, 2024 | -0.01 | -0.10 | +90.0% |
| Aug 8, 2024 | -0.14 | -0.21 | +33.3% |
News
Coherus BioSciences Q3 2026 Earnings PreviewSeeking Alpha · Nov 8, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
51No pass
Philip Fisher
52No pass
Peter Lynch
42No pass
Joel Greenblatt
2No pass
Charlie Munger
45No pass
Terry Smith
40No pass
Questions about Coherus Oncology
Is Coherus Oncology a good stock to buy?
A strong, very profitable business, and the price looks low. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Coherus Oncology AI analysis
What does Coherus Oncology do?
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. It is in Biotechnology.
Does Coherus Oncology pay a dividend?
No. Coherus Oncology does not pay a dividend at the moment.
Is Coherus Oncology stock halal?
No. Coherus Oncology does not pass our halal screen: its debt is 50% of its market value, at or above the 33% limit. How we check
How has Coherus Oncology stock done over the past year?
Down 58.3% over the past twelve months, to $0.53. It traded between $0.53 and $2.51 and is 79.1% below its high.
Who are Coherus Oncology's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Coherus Oncology's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.